Дизайн, конструирование и изучение свойств поли-CTL-эпитопного Т-клеточного иммуногена — кандидата ДНК-вакцины против ВИЧ-1/СПИД
Диссертация
Несмотря на то, что в последнее время разрабатываются новые обещающие подходы, нацеленные на индукцию нейтрализующих антител, акцент многих исследователей сместился в сторону индукции клеточного иммунитета, так как появились убедительные доказательства, что ответы цитотоксических Т-лимфоцитов (CD8+ CTL), ассоциированные с ВИЧ-инфекцией, являются важными медиаторами противовирусного иммунитета и… Читать ещё >
Список литературы
- Berzofsky J.A., Ahlers J.D., Belyakov I.M. Strategies for designing and optimizing newgeneration vaccines //Nat. Rev. Immunol. 2001. V. 1. No. 3. P. 209−219.
- Letvin N.L. Progress in the development of an HIV-1 vaccine // Science. 1998. V. 280. No.5371. P.1875−1880.
- Berzofsky J.A., Ahlers J.D., Janik J., Morris J., Oh S, Terabe M., Belyakov I.M. Progress onnew vaccine strategies against chronic viral infections // J. Clin. Invest. 2004. V. 114. No. 4. P. 450−462.
- Ogg G.S., Jin X., Bonhoeffer S, Dunbar P.R., Nowak M.A., Monard S., Segal J.P., Cao Y.,
- Rowland-Jones S.L., Cerundolo V., Hurley A., Markowitz M., Ho D.D., Nixon D.F., McMichael A.J. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA // Science. 1998. V. 279. No. 5359. P. 2103−2106.
- Price D.A., Sewell A.K., Dong Т., Tan R., Goulder P.J., Rowland-Jones S.L., Phillips R.E.
- Antigen-specific release of beta-chemokines by anti-HIV-1 cytotoxic T lymphocytes // Curr. Biol. 1998. V. 8. No. 6. P. 355−358.
- Wagner L., Yang O.O., Garcia-Zepeda E.A., Ge Y., Kalams S.A., Walker B.D., Pasternack
- M.S., Luster A.D. Beta-chemokines are released from HIV-1-specific cytolytic T-cell granules complexed to proteoglycans //Nature. 1998. V. 391. No. 6670. P. 908−911.
- Binley J.M., Sanders R.W., Clas В., Schuelke N., Master A., Guo Y., Kajumo F., Anselma D.J.,
- Hanke Т., Blanchard T.J., Schneider J., Ogg G.S., Tan R., Becker M., Gilbert S.C., Hill A.V.,
- Smith G.L., McMichael A. Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice // J. Gen. Virol. 1998. V. 79 (Pt 1). P. 83−90.
- Напке Т., Schneider J, Gilbert S.C., Hill A.V., McMichael A. DNA multi-CTL epitopevaccines for HIV and Plasmodium falciparum: immunogenicity in mice // Vaccine. 1998. V. 16. No. 4. P. 426−435.
- Напке Т., Blanchard T.J., Schneider J., Hannan C.M., Becker M., Gilbert S.C., Hill A.V.,
- Smith G.L., McMichael A. Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime // Vaccine. 1998. V. 16. No. 5. P. 439−445.
- Thomson S.A., Khanna R., Gardner J., Burrows S.R., Coupar В., Moss D.J., Suhrbier A.
- Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design // Proc. Natl. Acad. Sci. U. S. A. 1995. V. 92. No. 13. P. 5845−5849.
- Thomson S.A., Elliott S.L., Sherritt M.A., Sproat K.W., Coupar B.E., Scalzo A.A., Forbes
- C.A., Ladhams A.M., Mo X.Y., Tripp R.A., Doherty P.C., Moss D.J., Suhrbier A. Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes // J. Immunol. 1996. V. 157. No. 2. P. 822−826.
- Letvin N.L. Progress in the development of an HIV-1 vaccine // Science. 1998. V. 280. No.5371. P.1875−1880.
- Rowland-Jones S., Sutton J., Ariyoshi K., Dong Т., Gotch F., McAdam S., Whitby D., Sabally
- S., Gallimore A., Corrah Т.,. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women//Nat. Med. 1995. V. 1. No. 1. P. 59−64.
- Firat H., Tourdot S., Ureta-Vidal A., Scardino A., Suhrbier A., Buseyne F., Riviere Y., Danos
- Karpenko L.I., Nekrasova N.A., Ilyichev A.A., Lebedev L.R., Ignatyev G.M., Agafonov A.P.,
- Zaitsev B.N., Belavin P.A., Seregin S.V., Danilyuk N.K., Babkina I.N., Bazhan S.I.
- Comparative analysis using a mouse model of the immunogenicity of artificial VLP and attenuated Salmonella strain carrying a DNA-vaccine encoding HTV-1 polyepitope CTL-immunogen//Vaccine. 2004. V. 22. No. 13−14. P. 1692−1699.
- Woodberry Т., Gardner J., Mateo L., Eisen D., Medveczky J., Ramshaw I.A., Thomson S.A.,
- Ffrench R.A., Elliott S.L., Firat H., Lemonnier F.A., Suhrbier A. Immunogenicity of a human immunodeficiency virus (HIV) polytope vaccine containing multiple HLA A2 HIV CD8(+) cytotoxic T-cell epitopes // J. Virol. 1999. V. 73. No. 7. P. 5320−5325.
- Barre-Sinoussi F., Chermann J.C., Rey F., Nugeyre M.T., Chamaret S., Gruest J., Dauguet C.,
- Axler-Blin C., Vezinet-Brun F., Rouzioux C., Rozenbaum W., Montagnier L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS) // Science. 1983. V. 220. No. 4599. P. 868−871.
- Levy J.A., Shimabukuro J. Recovery of AIDS-associated retroviruses from patients with AIDSor AIDS-related conditions and from clinically healthy individuals // J. Infect. Dis. 1985. V. 152. No. 4. P. 734−738.
- Oroszlan S., Luftig R.B. Retroviral proteinases // Curr. Top. Microbiol. Immunol. 1990. V.157. P.153−185.
- Electronic Citation. Warner C.Greene, B. Matija Peterlin. AnonymousHIV InSite Knowledge Base Chapter. 2005. // center for HIV information. Anonymous
- Хаитов P.M., Игнатьева Г. А. СПИД. М.:Медицина, 1992.
- Bryant М., Ratner L. Myristoylation-dependent replication and assembly of humanimmunodeficiency virus 1 // Proc. Natl. Acad. Sci. U. S. A. 1990. V. 87. No. 2. P. 523−527.
- Gottlinger H.G., Sodroski J.G., Haseltine W.A. Role of capsid precursor processing and myristoylation in morphogenesis and infectivity of human immunodeficiency virus type 1 // Proc. Natl. Acad. Sci. U. S. A. 1989. V. 86. No. 15. P. 5781−5785.
- Jacks Т., Power M.D., Masiarz F.R., Luciw P.A., Barr P.J., Varmus H.E. Characterization of ribosomal frameshifting in HIV-1 gag-pol expression //Nature. 1988. V. 331. No. 6153. P. 280−283.
- Parkin N.T., Chamorro M., Varmus H.E. Human immunodeficiency virus type 1 gag-polframeshifting is dependent on downstream mRNA secondary structure: demonstration by expression in vivo // J. Virol. 1992. V. 66. No. 8. P. 5147−5151.
- Miller M., Jaskolski M., Rao J.K., Leis J., Wlodawer A. Crystal structure of a retroviralprotease proves relationship to aspartic protease family //Nature. 1989. V. 337. No. 6207. P. 576−579.
- Bushman F.D., Fujiwara Т., Craigie R. Retroviral DNA integration directed by HIVintegration protein in vitro // Science. 1990. V. 249. No. 4976. P. 1555−1558.
- Bernstein H.B., Tucker S.P., Kar S. R, McPherson S.A., McPherson D.T., Dubay J.W., 1. bowitz J., Compans R.W., Hunter E. Oligomerization of the hydrophobic heptad repeat of gp41 // J. Virol. 1995. V. 69. No. 5. P. 2745−2750.
- Kim S.Y., Byrn R., Groopman J., Baltimore D. Temporal aspects of DNA and RNA synthesisduring human immunodeficiency virus infection: evidence for differential gene expression // J. Virol. 1989. V. 63. No. 9. P. 3708−3713.
- Heinzinger N.K., Bukinsky M.I., Haggerty S.A., Ragland A.M., Kewalramani V., Lee M.A.,
- Schubert U., Bour S., Ferrer-Montiel A.V., Montal M., Maldarell F., Strebel K. The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains // J. Virol. 1996. V. 70. No. 2. P. 809−819.
- Strebel K, Daugherty D, Clouse K, Cohen D., Folks Т., Martin M.A. The HIV 'A' (sor) gene product is essential for virus infectivity // Nature. 1987. V. 328. No. 6132. P. 728−730.
- Malim M.H., Emerman M. HIV-1 sequence variation: drift, shift, and attenuation // Cell. 2001.
- V. 104. No. 4. P. 469−472.
- Louwagie J., McCutchan F.E., Peeters M., Brennan T.P., Sanders-Buell E., Eddy G.A., van der
- G.G., Fransen K., Gershy-Damet G.M., Deleys R.,. Phylogenetic analysis of gag genes from 70 international HIV-1 isolates provides evidence for multiple genotypes // AIDS. 1993. V. 7. No. 6. P. 769−780.
- Descamps D., Collin G., Letourneur F., Apetrei C., Damond F., Loussert-Ajaka I., Simon F.,
- Saragosti S., Brun-VezinetF. Susceptibility of human immunodeficiency virus type 1 group О isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses // J. Virol. 1997. V.71.No. 11. P. 8893−8898.
- Osmanov S., Pattou C., Walker N., Schwardlander В., Esparza J. Estimated global distributionand regional spread of HIV-1 genetic subtypes in the year 2000 // J. Acquir. Immune. Defic. Syndr. 2002. V. 29. No. 2. P. 184−190.
- Osmanov S., Pattou C., Walker N., Schwardlander В., Esparza J. Estimated global distributionand regional spread of HIV-1 genetic subtypes in the year 2000 // J. Acquir. Immune. Defic. Syndr. 2002. V. 29. No. 2. P. 184−190.
- Osmanov S., Pattou C., Walker N., Schwardlander В., Esparza J. Estimated global distributionand regional spread of HIV-1 genetic subtypes in the year 2000 // J. Acquir. Immune. Defic. Syndr. 2002. V. 29. No. 2. P. 184−190.
- Gao F., Robertson D.L., Morrison S.G., Hui H., Craig S., Decker J., Fultz P.N., Girard M.,
- Shaw G.M., Hahn B.H., Sharp P.M. The heterosexual human immunodeficiency virus type 1epidemic in Thailand is caused by an intersubtype (A/E) recombinant of African origin // J. Virol. 1996. V. 70. No. 10. P. 7013−7029.
- Carr J.K., Salminen M.O., Albert J., Sanders-Buell E., Gotte D., Birx D.L., McCutchan F.E. Full genome sequences of human immunodeficiency virus type 1 subtypes G and A/G intersubtype recombinants//Virology. 1998. V. 247. No. 1. P. 22−31.
- Liitsola K., Tashkinova I., Laukkanen Т., Korovina G., Smolskaja Т., Momot O.,
- Paraskevis D., Magiorkinis E., Magiorkinis G., Anastassopoulou C., Lazanas M., Chrysos G.,
- Laukkanen Т., Carr J.K., Janssens W., Liitsola K., Gotte D., McCutchan F.E., Op d.C.,
- Cornelissen M., Heyndrickx L., van der G.G., Salminen M.O. Virtually full-length subtype F and F/D recombinant HIV-1 from Africa and South America // Virology. 2000. V. 269. No. 1. P. 95−104.
- Hirsch V.M., Johnson P.R. Pathogenic diversity of simian immunodeficiency viruses // Virus
- Res. 1994. V. 32. No. 2. P. 183−203.
- Bailes E., Gao F., Bibollet-Ruche F., Courgnaud V., Peeters M., Marx P.A., Hahn B.H., Sharp
- P.M. Hybrid origin of SIV in chimpanzees // Science. 2003. V. 300. No. 5626. P. 1713
- Letvin N.L., King N.W. Immunologic and pathologic manifestations of the infection of rhesusmonkeys with simian immunodeficiency virus of macaques // J. Acquir. Immune. Defic. Syndr. 1990. V. 3. No. 11. P. 1023−1040.
- Mascola J.R. Defining the protective antibody response for HIV-1 // Curr. Mol. Med. 2003. V.3. No. 3. P. 209−216.
- Mascola J.R., Lewis M.G., Stiegler G., Harris D., VanCott T.C., Hayes D., Louder M.K.,
- Montefiori DC. HIV-1 specific neutralizing antibodies // In: Retroviral Immunology / Eds. G
- Pantaleo, В Walker. Totowa, N1: Humana, 2001. P. 191−211.
- Reitter I.N., Means R.E., Desrosiers R.C. A role for carbohydrates in immune evasion in AIDS
- Nat. Med. 1998. V. 4. No. 6. P. 679−684.
- Chan D.C., Fass D., Berger J.M., Kim P. S. Core structure of gp41 from the HIV envelopeglycoprotein// Cell. 1997. V. 89. No. 2. P. 263−273.
- Parren P.W., Burton D.R. The antiviral activity of antibodies in vitro and in vivo // Adv.1.munol. 2001. V. 77. P. 195−262.
- Cocchi F., DeVico A.L., Garzino-Demo A., Arya S.K., Gallo R.C., Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells // Science. 1995. V. 270. No. 5243. P. 1811−1815.
- Walker C.M., Moody D.J., Stites D.P., Levy J.A. CD8+ lymphocytes can control HIVinfection in vitro by suppressing virus replication // Science. 1986. V. 234. No. 4783. P. 15 631 566.
- Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., Farthing С., Ho
- D.D. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome // J. Virol. 1994. V. 68. No. 7. P. 4650−4655.
- Richman D.D., Wrin Т., Little S.J., Petropoulos C.J. Rapid evolution of the neutralizingantibody response to HIV type 1 infection // Proc. Natl. Acad. Sci. U. S. A. 2003. V. 100. No. 7. P. 4144−4149.
- Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar
- M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., Shaw G.M. Antibody neutralization and escape by HIV-1 // Nature. 2003. V. 422. No. 6929. P. 307 312.
- Berkower I., Murphy D., Smith C.C., Smith G.E. A predominant group-specific neutralizingepitope of human immunodeficiency virus type 1 maps to residues 342 to 511 of the envelope glycoprotein gpl20// J. Virol. 1991. V. 65. No. 11. P. 5983−5990.
- Dalgleish A.G., Chanh T.C., Kennedy R.C., Kanda P, Clapham P.R., Weiss R.A. Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide // Virology. 1988. V. 165. No. 1. P. 209−215.
- Ho D.D., Sarngadharan M.G., Hirsch M.S., Schooley R.T., Rota T.R., Kennedy R.C., Chanh
- T.C., Sato V.L. Human immunodeficiency virus neutralizing antibodies recognize severalconserved domains on the envelope glycoproteins // J. Virol. 1987. V. 61. No. 6. P. 20 242 028.
- Steimer K.S., Klasse P.J., McKeating J.A. HIV-1 neutralization directed to epitopes other than linear V3 determinants // AIDS. 1991. V. 5 Suppl 2. P. S135-S143
- Levy J.A. Pathogenesis of human immunodeficiency virus infection // Microbiol. Rev. 1993.1. V. 57. No. l.P. 183−289.
- Levy J.A. Pathogenesis of human immunodeficiency virus infection // Microbiol. Rev. 1993.1. V. 57. No. l.P. 183−289.
- Mosmann T.R., Coffman R.L. Heterogeneity of cytokine secretion patterns and functions ofhelper T cells // Adv. Immunol. 1989. V. 46. P. 111−147.
- Clerici M., Shearer G.M. A TH1~>TH2 switch is a critical step in the etiology of HIV infection //Immunol. Today. 1993. V. 14. No. 3. P. 107−111.
- Ozaki S., York-Jolley J., Kawamura H., Berzofsky J.A. Cloned protein antigen-specific, Ia-restricted T cells with both helper and cytolytic activities: mechanisms of activation and killing // Cell Immunol. 1987. V. 105. No. 2. P. 301−316.
- Hammond S.A., Bollinger R.C., Stanhope P.E., Quinn T.C., Schwartz D., Clements M.L.,
- Germain R.N. Immunology. The ins and outs of antigen processing and presentation // Nature.1986. V. 322. No. 6081. P. 687−689.
- Daniel M.D., Kirchhoff F., Czajak S.C., Sehgal P.K., Desrosiers R.C. Protective effects of alive attenuated SIV vaccine with a deletion in the nef gene // Science. 1992. V. 258. No. 5090. P. 1938−1941.
- Baba T.W., Jeong Y.S., Pennick D., Bronson R., Greene M.F., Ruprecht R.M. Pathogenicity oflive, attenuated SIV after mucosal infection of neonatal macaques // Science. 1995. V. 267. No. 5205. P. 1820−1825.
- Murphey-Corb M., Martin L.N., Davison-Fairburn В., Montelaro R.C., Miller M., West M.,
- Ohkawa S., Baskin G.B., Zhang J.Y., Putney S.D.,. A formalin-inactivated whole SIV vaccine confers protection in macaques // Science. 1989. V. 246. No. 4935. P. 1293−1297.
- Karpenko L.I., Bazhan S.I., Ignat’ev G.M., Lebedev L.R., Il’ichev A.A., Sandakhchiev L.S.
- Artificial anti-HIV immunogens and methods of their delivery. // Vestn. Ross. Akad. Med. Nauk. 2003. No. l.P. 24−30.
- Perkus M.E., Tartaglia J., Paoletti E. Poxvirus-based vaccine candidates for cancer, AIDS, andother infectious diseases //J. Leukoc. Biol. 1995. V. 58. No. 1. P. 1−13.
- Waine G.J., McManus D.P. Nucleic acids: vaccines of the future // Parasitol. Today. 1995. V.11. No. 3. P. 113−116.
- Moss D.J., Schmidt C., Elliott S., Suhrbier A., Burrows S., Khanna R. Strategies involved indeveloping an effective vaccine for EBV-associated diseases // Adv. Cancer Res. 1996. V. 69. P. 213−245.
- Couillin I., Culmann-Penciolelli В., Gomard E., Choppin J., Levy J.P., Guillet J.G., Saragosti
- S. Impaired cytotoxic T lymphocyte recognition due to genetic variations in the mainimmunogenic region of the human immunodeficiency virus 1 NEF protein // J. Exp. Med. 1994. V. 180. No. 3. P. 1129−1134.
- Udhayakumar V., Shi Y.P., Kumar S., Jue D.L., Wohlhueter R.M., Lai A.A. Antigenicdiversity in the circumsporozoite protein of Plasmodium falciparum abrogates cytotoxic-T-cell recognition // Infect. Immun. 1994. V. 62. No. 4. P. 1410−1413.
- Albini A., Ferrini S., Benelli R., Sforzini S., Giunciuglio D., Aluigi M.G., Proudfoot A.E.,
- Alouani S, Wells T.N., Mariani G., Rabin R.L., Farber J.M., Noonan D.M. HIV-1 Tat protein mimicry of chemokines // Proc. Natl. Acad. Sci. U. S. A. 1998. V. 95. No. 22. P. 1 315 313 158.
- Cantalloube H.M., Nahum C.E., Zagury J.F. Screening of protein sequences databanks by Automat for search of host sequences integration and/or autoimmune disorders induction by retroviruses//Biomed. Pharmacother. 1994. V. 48. No. 1. P. 17−26.
- Chen Y.H., DierichM.P. A common immunological epitope existing between HIV-1 gp41 and human interferon-alpha and -beta // Immunobiology. 1998. V. 198. No. 4. P. 333−342.
- Nakamura M.C., Nakamura R.M. Contemporary concepts of autoimmunity and autoimmune diseases // J. Clin. Lab Anal. 1992. V. 6. No. 5. P. 275−289.
- Eroshkin A.M., Karginova E.A., Gileva I.P., Lomakin A.S., Lebedev L.R., Kamyinina T.P., Pereboev A.V., Ignat’ev G.M. Design of four-helix bundle protein as a candidate for HIV vaccine // Protein Eng. 1995. V. 8. No. 2. P. 167−173.
- Donnelly J.J., Ulmer J.B., Shiver J.W., Liu M.A. DNA vaccines // Annu. Rev. Immunol. 1997. V. 15. P. 617−648.
- Ramakrishna L. Anand K.K., Mohankumar K.M., Ranga U. Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization // J. Virol. 2004. V. 78. No. 17. P. 9174−9189.
- Yadava A., Ockenhouse C.F. Effect of codon optimization on expression levels of a functionally folded malaria vaccine candidate in prokaryotic and eukaryotic expression systems // Infect. Immun. 2003. V. 71. No. 9. P. 4961−4969.
- Zhang S., Magnusson G. Kilham polyomavirus: activation of gene expression and DNA replication in mouse fibroblast cells by an enhancer substitution // J. Virol. 2001. V. 75. No. 21. P. 10 015−10 023.
- Nimal S., Heath A.W., Thomas M.S. Enhancement of immune responses to an HIV gpl20 DNA vaccine by fiision to TNF alpha cDNA // Vaccine. 2006. V. 24. No. 16. P. 3298−3308.
- Henke A., Rohland N., Zell R., Wutzler P. Co-Expression of Interleukin-2 by a Bicistronic Plasmid Increases the Efficacy of DNA Immunization to Prevent Influenza Virus Infections // Intervirology. 2006. V. 49. No. 4. P. 249−252.
- Kasturi S.P., Sachaphibulkij К., Roy К. Covalent conjugation of polyethyleneimine on biodegradable microparticles for delivery of plasmid DNA vaccines // Biomaterials. 2005. V. 26. No. 32. P. 6375−6385.
- Little S.R., Lynn D.M., Puram S.V., Danger R. Formulation and characterization of poly (beta amino ester) microparticles for genetic vaccine delivery // J. Control Release. 2005. V. 107. No. 3. P. 449−462.
- Pfeifer B.A., Burdick J.A., Little S.R., Langer R. Poly (ester-anhydride):poly (beta-amino ester) micro- and nanospheres: DNA encapsulation and cellular transfection // Int. J. Pharm. 2005. V. 304. No. 1−2. P. 210−219.
- Boyer J.D., Chattergoon M., Muthumani K., Kudchodkar S., Kim J., Bagarazzi M., Pavlakis G., Sekaly R., Weiner D.B. Next generation DNA vaccines for HIV-1 // J. Liposome Res.2002. V. 12. No. 1−2. P. 137−142.
- Shen L, Chen Z. W, Miller M. D, Stallard V., Mazzara G.P., Panicali D.L., Letvin N.L. Recombinant virus vaccine-induced SIV-specific CD8+ cytotoxic T lymphocytes // Science. 1991. V. 252. No. 5004. P. 440−443.
- Redfield R.R., Wright D.C., James W.D., Jones T.S., Brown C., Burke D.S. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease // N. Engl. J. Med. 1987. V. 316. No. 11. P. 673−676.
- Shiver J.W., Emini E.A. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors// Annu. Rev. Med. 2004. V. 55. P. 355−372.
- Shiver J. W, Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R. K, Zhang Z.Q., Simon
- A.J., Trigona W.L., Dubey S.A., Huang L., Harris V.A., Long R.S., Liang X., Handt L. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity //Nature. 2002. V. 415. No. 6869. P. 331−335.
- Letvin N.L., Huang Y., Chakrabarti B.K., Xu L., Seaman M.S., Beaudry K., Korioth-Schmitz
- B., Yu F, Rohne D., Martin K.L., Miura A, Kong W.P., Yang Z.Y., Gelman R.S., Golubeva O.G. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys // J. Virol. 2004. V. 78. No. 14. P. 7490−7497.
- Dudek Т., Knipe D.M. Replication-defective viruses as vaccines and vaccine vectors // Virology. 2006. V. 344. No. 1. P. 230−239.
- Goldberg A.L., Rock K.L. Proteolysis, proteasomes and antigen presentation // Nature. 1992. V. 357. No. 6377. P. 375−379.
- Oldstone M.B. Viral persistence // Cell. 1989. V. 56. No. 4. P. 517−520.
- Rammensee H.G., Falk K., Rotzschke О. MHC molecules as peptide receptors // Curr. Opin. Immunol. 1993. V. 5. No. 1. P. 35−44.
- York I.A., Rock K.L. Antigen processing and presentation by the class I major histocompatibility complex//Annu. Rev. Immunol. 1996. V. 14. P. 369−396.
- Heemels M.T., Ploegh H.L. Substrate specificity of allelic variants of the TAP peptide transporter // Immunity. 1994. V. 1. No. 9. P. 775−784.
- Rammensee H.G., Falk K., Rotzschke O. MHC molecules as peptide receptors // Curr. Opin. Immunol. 1993. V. 5. No. 1. P. 35−44.
- Lalvani A., Aidoo M., Allsopp C. E, Plebanski M., Whittle H.C., Hill A.V. An HLA-based approach to the design of a CTL-inducing vaccine against Plasmodium falciparum // Res. Immunol. 1994. V. 145. No. 6. P. 461−468.
- Sidney J., Grey H.M., Kubo R.T., Sette A. Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs // Immunol. Today. 1996. V. 17. No. 6. P. 261−266.
- Hanke Т., McMichael A. Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS //Immunol. Lett. 1999. V. 66. No. 1−3. P. 177−181.
- Maksiutov A.Z., Bachinskii A.G., Bazhan S.I. Searching for local similarities between HIV-1 and human proteins. Application to vaccines. // Mol. Biol. (Mosk). 2002. V. 36. No. 3. P. 447−459.
- Maksyutov A.Z., Bachinskii A.G., Bazhan S.I., Ryzhikov E.A., Maksyutov Z.A. Exclusion of HIV epitopes shared with human proteins is prerequisite for designing safer AIDS vaccines // J. Clin. Virol. 2004. V. 31 Suppl 1. P. S26-S38
- Itakura K., Hirose Т., Crea R., Riggs A.D., Heyneker H.L., Bolivar F., Boyer H.W. Expression in Escherichia coli of a chemically synthesized gene for the hormone somatostatin // Science. 1977. V. 198. No. 4321. P. 1056−1063.
- Mullis K.B. The unusual origin of the polymerase chain reaction // Sci. Am. 1990. V. 262. No. 4. P. 56−5.
- Dillon P.J., Rosen C.A. A rapid method for the construction of synthetic genes using the polymerase chain reaction // Biotechniques. 1990. V. 9. No. 3. P. 298, 300.
- Smith H.O., Hutchison C.A., III, Pfannkoch C., Venter J.C. Generating a synthetic genome by whole genome assembly: phiX174 bacteriophage from synthetic oligonucleotides // Proc. Natl. Acad. Sci. U. S. A. 2003. V. 100. No. 26. P. 15 440−15 445.
- Prodromou C., Pearl L.H. Recursive PCR: a novel technique for total gene synthesis // Protein Eng. 1992. V. 5. No. 8. P. 827−829.
- Stemmer W.P., Crameri A., Ha K.D., Brennan T.M., Heyneker H.L. Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides // Gene. 1995. V. 164. No. l.P. 49−53.
- Hoover D.M., Lubkowski J. DNA Works: an automated method for designing oligonucleotides for PCR-based gene synthesis // Nucleic Acids Res. 2002. V. 30. No. 10. P. e43
- Mandecki W., Hayden M.A., Shallcross M.A., Stotland E. A totally synthetic plasmid for general cloning, gene expression and mutagenesis in Escherichia coli // Gene. 1990. V. 94. No. l.P. 103−107.
- Cello J., Paul A.V., Wimmer E. Chemical synthesis ofpoliovirus cDNA: generation of infectious virus in the absence of natural template // Science. 2002. V. 297. No. 5583. P. 1016−1018.
- Hutchison C. A, Peterson S. N, Gill S. R, Cline R. T, White O, Fraser C. M, Smith H. O, Venter J.C. Global transposon mutagenesis and a minimal Mycoplasma genome // Science. 1999. V. 286. No. 5447. P. 2165−2169.
- Walsh С. Antibiotics: Actions, Origins, Resistance. Washington, DC: Am. Soc. Microbiol., 2003.
- Kodumal S.J., Patel K.G., Reid R., Menzella H.G., Welch M., Santi D.V. Total synthesis of long DNA sequences: synthesis of a contiguous 32-kb polyketide synthase gene cluster // Proc. Natl. Acad. Sci. U. S. A. 2004. V. 101. No. 44. P. 15 573−15 578.
- Daniliuk N.K., Serpinskii O.I., Siniakov A.N. Design of recombinant-stable plasmids of the pFH series. // Bioorg. Khim. 1991. V. 17. No. 1. P. 81−87.
- Sambrook J., Maniatis Т., Fritsch E.F. Molecular cloning a laboratory manual. Cold Spring Harbor, N. Y: Cold Spring Harbor Laboratory, 1989.
- Rychlik W., Rhoads R.E. A computer program for choosing optimal oligonucleotides for filter hybridization, sequencing and in vitro amplification of DNA // Nucleic Acids Res. 1989. V. 17. No. 21. P. 8543−8551.
- Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4 //Nature. 1970. V. 227. No. 5259. P. 680−685.
- Goldberg A.L., Rock K.L. Proteolysis, proteasomes and antigen presentation // Nature. 1992. V. 357. No. 6377. P. 375−379.
- Oldstone M.B. Viral persistence // Cell. 1989. V. 56. No. 4. P. 517−520.
- Rammensee H.G., Falk K., Rotzschke O. MHC molecules as peptide receptors // Curr. Opin. Immunol. 1993. V. 5. No. 1. P. 35−44.
- York I.A., Rock K.L. Antigen processing and presentation by the class I major histocompatibility complex // Annu. Rev. Immunol. 1996. V. 14. P. 369−396.
- Lalvani A., Aidoo M., Allsopp C.E., Plebanski M, Whittle H.C., Hill A.V. An HLA-based approach to the design of a CTL-inducing vaccine against Plasmodium falciparum // Res. Immunol. 1994. V. 145. No. 6. P. 461−468.
- Sidney J., Grey H.M., Kubo R.T., Sette A. Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs // Immunol. Today. 1996. V. 17. No. 6. P. 261−266.
- Maksiutov A.Z., Bachinskii A.G., Bazhan S.I. Searching for local similarities between HIV-1 and human proteins. Application to vaccines. // Mol. Biol. (Mosk). 2002. V. 36. No. 3. P. 447−459.
- Livingston B.D., Newman M., Crimi C., McKinney D., Chesnut R., Sette A. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines // Vaccine. 2001. V. 19. No. 32. P. 4652−4660.
- Perkus M.E., Tartaglia J., Paoletti E. Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases // J. Leukoc. Biol. 1995. V. 58. No. 1. P. 1−13.
- Guarnieri F.G., Arterburn L.M., Penno M.B., Cha Y., August J.T. The motif Tyr-X-X-hydrophobic residue mediates lysosomal membrane targeting of lysosome-associated membrane protein 1 // J. Biol. Chem. 1993. V. 268. No. 3. P. 1941−1946.
- Ratner L., Haseltine W., Patarca R., Livak K.J., Starcich В., Josephs S.F., Doran E.R., Rafalski J.A., Whitehorn E.A., Baumeister K.,. Complete nucleotide sequence of the AIDS virus, HTLV-III //Nature. 1985. V. 313. No. 6000. P. 277−284.